| ID | 119073 |
| Author |
Bando, Hiroshi
Medical Research|Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
|
| Keywords | Triple receptor agonist
Dual receptor agonist
Incretin peptide
Glucagon-like peptide-1 (GLP-1)
Glucose-dependent insulinotropic polypeptide (GIP)
Glucagon (GCG)
Tirzepatide
|
| Content Type |
Journal Article
|
| Description | Recent trends for the treatment of type 2 diabetes (T2D) show dual or triple receptor agonists for incretins peptides. They are glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG). Triple receptor agonist includes LY3437943, in which clinical efficacy for 12 weeks was glucose -3.1 mmol/L, HbA1c -1.6% and weight -8.96 kg. Dual agonist includes tirzepatide (GIP/GLP-1) that shows remarkable efficacy for lowering blood glucose for T2D patients. Tirzepatide (10 mg/day) showed 20% of weight reduction at 72 weeks and was also effective for heart failure with preserved ejection fraction (HFpEF), non-alcoholic steatohepatitis (NASH) and major adverse cardiovascular events (MACE).
|
| Journal Title |
Journal of Diabetes, Obesity & Metabolism
|
| Publisher | Yumed Text
|
| Volume | 5
|
| Issue | 1
|
| Start Page | e109
|
| Published Date | 2022-12-21
|
| Rights | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/)
|
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
